EFTISARC-NEO Phase II results presented at CTOS 2025
Filed with ASX · · 3 pages · English
Story so far
Earlier from Immutep
- Immutep Receives A$4.6 million R&D Tax Incentive from French Government
- Immutep Receives A$4.6 million French R&D Tax Incentive
- Immutep Quarterly Activities Report Q1 FY26
- Primary Endpoint Met in STS Trial - presented at ESMO 2025
- Improved ORR in First Line NSCLC - presented at ESMO 2025
Later from Immutep
- Translational Data and Significant Pathologic Response Rates from EFTISARC-NEO Phase II Highlighted in Oral Presentation at CTOS 2025
- New data presentation from AIPAC-003 Phase II for SABCS
- Immutep to Present New Data from AIPAC-003 Phase II at the 2025 San Antonio Breast Cancer Symposium
- Immutep enters into Strategic Collaboration with Dr. Reddy's
- Immutep and Dr. Reddy’s enters into Strategic Collaboration for Commercialisation of an Innovative Oncology Drug, Eftilagimod Alfa
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep